Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of “Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $49.91.

Several brokerages recently weighed in on DYN. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th.

Dyne Therapeutics Trading Up 4.4 %

DYN stock opened at $14.14 on Friday. The company has a market capitalization of $1.44 billion, a P/E ratio of -3.97 and a beta of 1.16. Dyne Therapeutics has a twelve month low of $13.23 and a twelve month high of $47.45. The business has a 50 day simple moving average of $22.75 and a 200-day simple moving average of $31.89.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity

In other news, Director Jason P. Rhodes sold 782 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock worth $606,476 over the last 90 days. 20.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics during the 3rd quarter worth about $34,000. Point72 DIFC Ltd purchased a new stake in Dyne Therapeutics during the 3rd quarter worth about $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Dyne Therapeutics during the 3rd quarter worth about $62,000. Finally, KBC Group NV increased its position in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.